Targets and Tools: Protein Kinases
Discover how to populate your pipeline by uncovering novel kinase targets and pathways
Don’t let your most promising drug be shelved in clinical trials!
Join us to discover potential toxicities in early stage discovery and plan ahead for success at Informa Life Sciences’ 2010 Protein Kinases Congress - Brand NEW sessions for 2010 include:
- Inhibitor selectivity: Optimising your kinase based therapeutics - Hear from Bayer Schering Pharma, Novartis and Almirall on how they have approached where to draw he line on selectivity
- Progressing kinase inhibitors into clinical trials: Gaining success beyond phase 1 - Essential insights on improving preclinical and clinical translation and ensuring your compound has the comprehensive safety profile it needs to progress
- Filling the R&D pipeline: Uncovering novel kinase targets and pathways. This session will highlight how by investing time into looking into the kinome new realistic opportunities can be discovered for future development
Do not miss 2010’s only European forum covering the discovery and development of Protein Kinases and how you can successfully progress these products into clinical trials – download the brochure today!
Highlights of Protein Kinase Congress 2010
Research in this field is fast moving and competition for the market share is fierce. Ensure that you keep ahead of the field and hear these topics new for 2010
- Inhibitor selectivity: Optimising your kinase based therapeutics read more
- Filing the R&D pipeline: Uncovering novel kinase targets and pathways read more
- Progressing kinase inhibitors into clinical trials: Gaining success beyond phase 1 read more
- Overcome kinase inhibitor screening challenges read more
- Hear 11 novel industry case studies read more
- 4 conferences, 1 location, 1 exhibition read more
- Choose from 7 additional workshops to maximise on your time out of the office read more
Post-Conference Workshop - Friday 19 March 2010
Allosteric Modulation as a successful drug target
Through presentations, small group exercises and discussion this workshop will guide you through this complex field to help you populate your pipelines with potential leads. Led by: Doriano Fabbro PhD, Novartis Pharma AG, Switzerland, Jose Duca, Merck Research Laboratories, USA and Pirthipal Singh, Singh Consultancy, UK
Sponsors
Exhibitors
Part of Drug Discovery Targets and Tools 2010 - explore these co-located events!
Dates and Venues
17 Mar 2010 - 18 Mar 2010
Maritim proArte Hotel
Our expert speaker panel
Pre-conference workshop, Tuesday 16 March 2010
Exploring Protein-Protein Interactions as Drug Targets
One of the most interesting aspects in this field at the moment is not the drug targets themselves, but the interaction with other proteins. This can be tissue specific or the co-activation or co-repression of co-factors. These can be agonists, antagonists or just have a more modulatory effect on the receptor. This workshop will lead you through this complex and emerging field through presentations, small group exercises and discussion.
Poll
What is your preference for kinase selectivity?
Reviews
"Very interesting. Fruitful discussions and questions"
"Overall a great mix of academic and industry, as well as good mix of basic science and chemistry"
"Excellent meeting overall for keeping up with advances in the field"
"An excellent venue for learning more about current advances in drug discovery from leaders in the industry"
